<DOC>
	<DOCNO>NCT01009866</DOCNO>
	<brief_summary>Purpose study : Primary Objective : Determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) MR1-1KDEL deliver intracerebrally convection-enhanced delivery ( CED ) patient supratentorial malignant brain tumor . Secondary Objective : Document radiographic response associate intracerebral CED MR1-1KDEL . Hypothesis : The investigator believe MR1-1KDEL effective anti-tumor agent patient supratentorial malignant brain tumor deliver CED . Design &amp; procedure : This protocol design primarily determine MTD DLT novel , tumor-specific immunotoxin , MR1-1KDEL . MR1-1KDEL deliver intracerebrally CED use 2 intracerebral catheter least one catheter place within enhance portion tumor . 124I-labeled albumin co-infused gadolinium PET MRI image obtain conclusion infusion monitor volume drug distribution leakage CSF space . Based preclinical toxicity study , start total drug dose 0.5μg ( 500ng ) represent 1/20th MTD rat . The infusion flow rate fix 0.5 mL/h two four catheter . A total 144 mLs drug solution deliver 72 hour . MR1-1KDEL dose escalation accomplish increase drug concentration allow flow rate infusion volume remain unchanged . Drug dose double successive cohort long DLTs observe follow : 25 ng/mL ( 2.4 μg ) ( start dose ) ; 50ng/mL ( 4.8μg ) ; 100 ng/mL ( 9.6μg ) ; 200ng/mL ( 19.2μg ) ; 400 ng/mL ( 38.4μg ) ; 800 ng/mL ( 76.8μg ) ; 1600 ng/mL ( 153.6μg ) . At least 3 patient enrolled cohort . All patient give cohort observe least two week follow infusion study drug patient next cohort treat . If patient give cohort experience DLT , dose escalate next cohort . If 1 3 patient give cohort experience DLT , 3 additional patient enter cohort . If 2 patient develop DLT cohort 3 6 patient , previous dose declare MTD . Patients follow 1 , 3 , 6 , 9 , 12 month interval toxicity adverse event , radiographic response , survival . Patients study progressive disease document . Risk/benefit assessment : This experimental study unforeseeable unexpected risk may involve .</brief_summary>
	<brief_title>Study Immunotoxin , MR1-1</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>Residual , progressive , recurrent supratentorial malignant brain tumor base image study measurable disease ( &gt; 0.5cm ) . Patient complete form radiation therapy prior toxin treatment . Karnofsky Performance score &gt; 70 . The presence target antigen , EGFRvIII , must identify tumor tissue immunohistochemistry . Platelet count &gt; 100 x 109/L ; PTT PT &lt; 120 % normal range . Creatinine &lt; 120 % normal range . Total bilirubin , SGOT , SGPT , alkaline phosphatase &lt; 300 % normal range . Patients pregnant , breastfeeding , unwilling practice effective method birth control . Patients know potentially anaphylactic allergic reaction iodine gadoliniumDTPA . Patients undergo MRI due obesity certain metal body ( specifically pacemaker , infusion pump , metal aneurysm clip , metal prosthesis , joint , rod plate ) . Patients recover toxic effect prior chemotherapy and/or radiation therapy . Patients impend , lifethreatening cerebral herniation syndrome . Patients subependymal CSF disease . Patients age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Malignant brain tumor</keyword>
	<keyword>GBM</keyword>
	<keyword>recurrent brain tumor</keyword>
	<keyword>Supratentorial malignant brain tumor</keyword>
	<keyword>astrocytomas</keyword>
	<keyword>ependymomas</keyword>
	<keyword>Residual , progressive , recurrent supratentorial malignant brain tumor base image study measurable</keyword>
	<keyword>disease ( &gt; 0.5cm ) .</keyword>
</DOC>